A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT03274492. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).
Study identification
- NCT ID
- NCT03274492
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
Interventions
- Polatuzumab Vedotin Drug
- Rituximab Drug
- Cyclophosphamide Drug
- Doxorubicin Drug
- Vincristine Drug
- Vincristine Placebo Drug
- Prednisone Drug
- Polatuzumab vedotin Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2017 (Actual)
- Primary completion
- Apr 30, 2026 (Actual)
- Completion
- Apr 30, 2026 (Actual)
- Last update posted
- May 8, 2026
2017 – 2026
United States locations
- U.S. sites
- 49
- U.S. states
- 25
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Southern Cancer Center | Daphne | Alabama | 36526 | — |
| City of Hope | Duarte | California | 91010 | — |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90024-6997 | — |
| Rocky Mountain Cancer Centers, LLP | Aurora | Colorado | 80012 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Florida Cancer Specialists - Fort Myers (New Hampshire Ct) | Fort Myers | Florida | 33901-8101 | — |
| Florida Cancer Specialists & Research Institute | St. Petersburg | Florida | 33705-1455 | — |
| Florida Cancer Specialists & Research Institute | St. Petersburg | Florida | 33705 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | — |
| James Graham Brown Cancer Center | Louisville | Kentucky | 40202-3229 | — |
| Ochsner Medical Center | New Orleans | Louisiana | 70121 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| The Johns Hopkins Hospital | Baltimore | Maryland | 21205 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Memorial Sloan Kettering Cancer Center at Westchester | Harrison | New York | 10604-3200 | — |
| New York University Cancer Cen | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Memorial Sloan Kettering Cancer Center - Commack | New York | New York | 10087-9049 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| University of North Carolina School of Medicine | Chapel Hill | North Carolina | 27514-4221 | — |
| Levine Cancer Institute - Clincal Trials Administration | Charlotte | North Carolina | 28204 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| The Ohio State University Comprehensive Cancer Center | Cleveland | Ohio | 44106 | — |
| University Hospitals Case Medical Center | Cleveland | Ohio | 44106 | — |
| Oncology Associates of Oregon, P.C | Eugene | Oregon | 97401 | — |
| Northwest Cancer Specialists - Portland (SW Barnes Rd) | Portland | Oregon | 97225 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15232-1309 | — |
| Medical University of South Carolina (MUSC) | Charleston | South Carolina | 29425 | — |
| Prisma Health ? Upstate | Greenville | South Carolina | 29615 | — |
| Greco-Hainesworth Centers for Research | Chattanooga | Tennessee | 37403 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203-1625 | — |
| Texas Oncology-Austin Midtown | Austin | Texas | 78705 | — |
| Texas Oncology San Antonio Medical Center | San Antonio | Texas | 78229 | — |
| Texas Oncology-Tyler | Tyler | Texas | 75702 | — |
| University of Utah | Salt Lake City | Utah | 84112 | — |
| Oncology Associates of Southwest Virginia, Inc. | Blacksburg | Virginia | 24060 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031-4618 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| West Virginia Uni Med. Center - Robert Byrd Health Science | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 160 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03274492, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2026 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03274492 live on ClinicalTrials.gov.